ANNORA PHARMA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ANNORA PHARMA, and what generic and branded alternatives to ANNORA PHARMA drugs are available?
ANNORA PHARMA has forty-one approved drugs.
There are four tentative approvals on ANNORA PHARMA drugs.
Summary for ANNORA PHARMA
| US Patents: | 0 |
| Tradenames: | 34 |
| Ingredients: | 34 |
| NDAs: | 41 |
| Patent Litigation for ANNORA PHARMA: | See patent lawsuits for ANNORA PHARMA |
Drugs and US Patents for ANNORA PHARMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annora Pharma | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 215761-002 | Jun 15, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Annora Pharma | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216800-001 | May 31, 2023 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Annora Pharma | LURASIDONE HYDROCHLORIDE | lurasidone hydrochloride | TABLET;ORAL | 218174-003 | Aug 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Annora Pharma | ELTROMBOPAG OLAMINE | eltrombopag olamine | FOR SUSPENSION;ORAL | 216620-001 | Apr 18, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
